Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IN B00004

Next Previous
X
Search
Drug Profile

IN B00004

Alternative Names: IN-B00004; IN-B015

Latest Information Update: 29 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CJ Cheiljedang Corp.
  • Developer HK inno.N
  • Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action CD56 antigen inhibitors; Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Multiple myeloma

Most Recent Events

  • 29 Mar 2024 IN B015 is available for licensing as of 29 Mar 2024. https://www.inno-n.com/eng/esg/csr/co_prosperity/esg_support
  • 14 Nov 2023 Phase-I clinical trials in Acute myeloid leukaemia in Europe (Parenteral) prior to November 2023
  • 14 Nov 2023 Phase-I clinical trials in Multiple myeloma in Europe (Parenteral) prior to November 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top